close
Add to watchlist
Dr Reddy Labs Depository Receipt (RDY) Healthcare, Biotechnology & Drugs
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. The company focuses on formulations, active pharmaceutical ingredients and intermediates, generic drugs, critical care products, biotechnology products, custom pharmaceutical services, and drug discovery. It conducts research in the areas of cancer, diabetes, metabolic disorders, cardiovascular diseases, inflammation, and bacterial infection. In addition, the company involves in contract manufacturing of generic prescription and over-the-counter products for branded and generic companies in the United States. Further, Dr. Reddy's offers central nervous system, pain management, gastrointestinal, respiratory, anti-infective, urology, women's health, spasticity, and alimentary tract related generics finished dosages. It markets its products in India, Russia, the United States, United Kingdom, Germany, South Africa, Brazil, China, Kazakhstan, Uzbekistan, Ukraine, Belarus, Vietnam, Romania, Venezuela, and Myanmar. The company has a co-development and commercialization agreement with Denmark based Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec International for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease; and an agreement with 7TM Pharma for the drug discovery collaboration on selected drug targets. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 33.86 |
| Volume | 171613 |
| Volume Avg | 198569 |
| 52 Week High | 39.37 |
| 52 Week Low | 28.75 |
| PE | 20.52 |
| PE (group average) | 39 |
| EPS Year | 1.67 |
| EPS change Q/Q | -5.26% |
| EPS change Q/Q Yr ago | -1000% |
| EPS change Q/Q next Q est | -100% |
| EPS change Y/Y | 1000% |
| REV change Q/Q | 1.5% |
| REV change Q/Q Yr ago | 9.76% |
| EPS next Q est | 0.00 |
| EPS next Y est | 2.08 |
| Divident Annual | 0.25 |
| Dividend Yield | 0.74% |